Click for Philadelphia, Pennsylvania Forecast


Cancer Center's
OncoLink and
Free On-Line Clinical Trial Match & Referral Service

OncoLink, the University of Pennsylvania Cancer Center's award-winning web site, and EmergingMed are pleased to announce the launch of a new Clinical Trial Match & Referral Service. Available free to visitors of, this service is the first phase of a three-year exclusive collaboration between Penn's Cancer Center and It enables visitors to learn about clinical trials available through the Cancer Center and to easily identify trials for which they or a loved one might be eligible. One of the largest cancer information web sites and cited as one of the best internet sources of medical information by the Journal of the American Medical Association (JAMA -May 24, 2001), OncoLink recently underwent a dramatic expansion and re-design. The updated graphics and layout introduce improved navigation features to better accommodate the over 11.2 million visits from patients, families and providers who access the site monthly. "We at EmergingMed and OncoLink share a steadfast commitment to improving patient access to cancer clinical trials and accelerating the process of finding better cancer treatments," said Courtney Hudson, chief executive officer and founder of EmergingMed. "Through this collaboration we can further empower patients with easy-to-locate treatment options they might otherwise never know about," added Dr. James Metz, assistant professor of radiation oncology at Penn and editor-in-chief of OncoLink. "At the same time, we've streamlined the process of getting eligible patients into clinical trials, making the experience as easy and convenient as possible."

Patients access the Clinical Trial Match & Referral Service at under "Treatment Options" and "Clinical Trials." From there, visitors can either view a listing of available trials by cancer type or they can fill out a simple on-line questionnaire to determine their eligibility. All submitted information is kept strictly confidential. Within seconds, a response will show if a patient's profile matches the enrollment criteria for any clinical trials at the Cancer Center. If a match is made with one or more clinical trials, an EmergingMed customer service specialist, upon request, will help facilitate contact with the team conducting the trials.

The service strives to respond to requests by phone the same day an application is submitted and within 48 hours for e-mail requests. Additional support for the Clinical Trials Match and Referral Service has been provided by Aventis Pharmaceuticals.

OncoLink was founded in 1994 by Penn cancer specialists who wanted to help cancer patients, families, health care professionals and the general public get accurate, timely cancer-related information-quickly and free of charge. Through it, the user can get information about specific types of cancer, news about research advances and updates on cancer treatment. OncoLink, which is managed and written by physicians and nurses of the Cancer Center, has been recognized as one of the leading health resources on the Web, reaching over 11 million hits per month. It's received numerous awards including the coveted Global Information Infrastructure Award in 1998.

EmergingMed was founded in January 2000 to offer cancer patients and their families a fast and easy way to find and understand available treatment options and to speed up drug development through increased enrollment in clinical trials. The Company's clients include Aventis Pharmaceuticals, Genentech, SuperGen, Clinical Research Group, ILEX Oncology, Protein Design Labs, Antigenics, and the University of Arizona Cancer Center. Based in New York City, EmergingMed is a private health services and hosted application provider.

For more information, call (212) 594-7990 or write to

Almanac, Vol. 48, No. 19, January 22, 2002


January 22, 2002
Volume 48 Number 19

In a message to the University community, President Judith Rodin notes that Penn must "take corrective steps now if we want to maintain a balanced budget."
Dr. Dawn Bonnell has been named Trustee Term Professor of Materials Science and Engineering.
Dr. Gary Molander has been named the Allan Day Term Professor.
Dr. Virginia Richards has been named the Kahn Term Professor.
An update on BEN Financials' first two weeks in operation includes a new Advisories web page for users.
The Division of Public Safety's Advisory Board seeks the input of the University community on their recommendations for expanding the PENNCard policy.
Interested in finding out about HERS, the summer institute for women in higher education? Two information sessions will provide the details. now contains a free on-line clinical trial match and referral service for patients who are attempting to locate all available treatment options.